Get the Stockscreener App
3.46
0.87%
0.03
After Hours:
3.29
-0.17
-4.91%
Amylyx Pharmaceuticals Inc stock is traded at $3.46, with a volume of 1.17M.
It is up +0.87% in the last 24 hours and down -10.59% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$3.43
Open:
$3.46
24h Volume:
1.17M
Relative Volume:
1.42
Market Cap:
$285.30M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
4.9429
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
-2.26%
1M Performance:
-10.59%
6M Performance:
+12.34%
1Y Performance:
+32.06%
1-Day Range:
$3.165
$3.60
1-Week Range:
$3.165
$3.825
52-Week Range:
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.46 | 285.30M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx stock upgraded at Mizuho on lead asset (AMLX:NASDAQ) - Seeking Alpha
Mizuho lifts Amylyx stock rating, doubles price target to $7 - Investing.com
Mizuho lifts Amylyx stock rating, doubles price target to $7 By Investing.com - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - markets.businessinsider.com
Don't Ignore The Insider Selling In Amylyx Pharmaceuticals - simplywall.st
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking - simplywall.st
Amylyx Pharmaceuticals Executives Unload Massive Stock Shares! - TipRanks
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock - Investing.com
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock - Investing.com India
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock - Investing.com
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock By Investing.com - Investing.com UK
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock - Investing.com
Amylyx Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Amylyx Pharmaceuticals Set to Reveal Latest Corporate Strategy at Major Healthcare Conference - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Does Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Still Look Hot This Week? - stocksregister.com
Charles Schwab Investment Management Inc. Lowers Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - Markets Insider
Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - Markets Insider
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock - Investing.com India
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Analysts Think Could Fell -201.37% From Current Levels - Stocks Register
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Shareholders that lost money on Amylyx Pharmaceuticals, Inc. (AMLX) should contact Levi & Korsinsky about pending Class ActionAMLX - ACCESS Newswire
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - Markets Insider
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga India
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
What is HC Wainwright’s Estimate for AMLX FY2025 Earnings? - Defense World
Research Analysts Issue Forecasts for AMLX Q1 Earnings - The AM Reporter
What is HC Wainwright’s Estimate for AMLX Q1 Earnings? - Defense World
Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position - TipRanks
HC Wainwright Reiterates “Buy” Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells $14,549 in stock By Investing.com - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider
Y Intercept Hong Kong Ltd Takes Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
March 2025's Top Penny Stocks To Watch - Yahoo Finance
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Up 30.5% in February - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):